529.9±60.0 °C at 760 mmHg
Store at 20-25 deg C (68-77 deg F), excursions permitted to 15-30 deg C (59-86 deg F).
2.91X10-8 mm Hg at 25 deg C (est)
Sitagliptin is a new type of anti-type II diabetes drug approved by the FDA and the first dipeptidyl peptidase-IV inhibitor drug used to treat type II diabetes. Sitagliptin's mechanism of action is different from previous oral hypoglycemic drugs. It improves the ability of diabetic patients' own pancreatic β cells to produce insulin and increases insulin secretion when blood sugar rises, thereby controlling the blood sugar level of diabetic patients. Clinical studies have shown that sitagliptin is an orally effective drug with good market prospects. It has a significant hypoglycemic effect when used alone or in combination with metformin and pioglitazone, and it is safe to take, well tolerated, and has fewer adverse reactions.